ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0490

Trends, Prevalence, and Predictors of Illicit Drug Use in CKD Patients

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Klomjit, Nattawat, Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
  • Chewcharat, Api, Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
  • Kattah, Andrea G., Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States
Background

Illicit drugs use is an important problem in general populations and chronic kidney disease (CKD) patients. Since 2012, marijuana has been legalized in several parts of United States, however, the trend and prevalence of illicit drug use in CKD patients in the current era remains unknown.

Methods

We conducted a cross-sectional analysis using the data from the National Health and Nutrition Examination Survey between 2007 and 2018. We calculated the trend of self-reported illicit drug use (marijuana, cocaine, heroin, methamphetamine, and intravenous drug use) and defined current use if the last use was within 1 year of the survey. We then assessed whether the use of illicit drugs is associated with CKD (defined by estimated glomerular filtration rate ≤ 60 ml/min/1.73 m2 and/or urine albumin-creatinine ratio (UACR) ≥ 30 mg/g), microalbuminuria (UACR≥ 30 mg/g) and macroalbuminuria (≥ 300 mg/g). Lastly, we assessed any predictors for drug use in CKD patients.

Results

Between 2007 to 2018, there were 22,214 adult patients between 18-59 years old. Of these, 2,148 had CKD as defined above. CKD patients were significantly older, more likely to be female, obese, cigarette smoker, alcohol drinker, and to have diabetes, and hypertension. We found that prevalence of marijuana (21.9% vs 21.9%, p=0.23), cocaine (4.9 vs 3.6, p=0.95) and methamphetamine (1.5% vs 1.3%, p=0.52) did not differ between CKD and non-CKD. However, heroin use (0.2% vs 0.5%, p=0.02) were significantly lower in CKD compared to non-CKD. Interestingly, there is significant trend towards increasing marijuana use in CKD patients overtime as prevalence increase from 17.3% in 2007-2010 to 21.7% in (2011-2014), and up to 26.5% in 2015-2018 (p trend 0.02). Recent Illicit drug use was not associated with CKD, microalbuminuria or macroalbuminuria. Age, black race, current smoker and alcohol drinking were significant predictors of drug use within 1 year in CKD patients.

Conclusion

In a national sample, marijuana was the most common illicit drug use among CKD patients and the trend of marijuana use in CKD patients is increasing, likely due to marijuana legalization. Age, black race, current smoker and alcohol drinking increase the odds of illicit drug use in CKD patients.